We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




C-Reactive Protein Preferred Test for Septic Joints

By LabMedica International staff writers
Posted on 14 Sep 2010
The C-reactive protein (CRP) serum assay was compared with the erythrocyte sedimentation rate (ESR) to help diagnose patients with septic joints.

A CRP test measures the amount of C-reactive protein in the blood. More...
CRP measures general levels of inflammation in the body. High levels of CRP are caused by infections and many chronic diseases. The sedimentation rate blood test measures how quickly red blood cells settle in a test tube in one hour. The more red cells that fall to the bottom of the test tube in one hour, the higher the ESR.

When inflammation is present in the body, certain proteins cause erythrocytes to stick together and fall more quickly than normal to the bottom of the tube. These proteins are produced by the liver and the immune system under many abnormal conditions, such as an infection, an autoimmune disease, or cancer.

However, neither test is definitive enough to predict where in the body inflammation is occurring. In a study carried out at the University of New Mexico (Albuquerque, NM, USA), CRP and ESR tests were carried out on 163 patients, of whom 72 had inflammatory joints, 44 had septic joints, and 47 were normal. Fifteen admitted to drug use and 43 to alcohol consumption and there were 120 males and 43 females. Sensitivities, specificities, positive and negative predictive values were obtained using the laboratory's positive cutoffs of 15 mm/h for ESR and 0.8 mg/L for CRP. The mean CRP for septic joints was 13 mg/L, 8.5 mg/L for inflammatory joints, and 6 mg/L for normal. The mean ESR for septic joints was 57 mm/h, 48 mm/h for inflammatory joints, and 43 mm/h for normal joints.

By univariate analysis, drug use and elevated CRPs were significantly associated with septic joints while alcohol use, ESRs, and gender were not. A regression model with four variables indicated that drug use and CRP were predictive of septic joint; alcohol and ESR were not. The authors concluded that CRP is helpful in determining the presence of a septic joint, but ESR is not. Their findings were published in the June 2010 issue of the Southern Medical Journal.

Related Links:

University of New Mexico


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.